Targeted Sequencing of Diagnostic Samples Correlated to Clinical Outcome: Data from the Nordic Mantle Cell Lymphoma (MCL2 and MCL3) Studies with Long-Term Follow-up

Eskelund Christian Winther; Hansen Jakob W.; Westman Maj Karoline; Freiburghaus Catja; Ek Sara; Pedersen Lone B.; Andersen Mette K.; Raty Riikka; Kolstad Arne; Jerkeman Mats; Brown Peter de Nully; Geisler Christian H.; Groenbaek Kirsten

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Targeted Sequencing of Diagnostic Samples Correlated to Clinical Outcome: Data from the Nordic Mantle Cell Lymphoma (MCL2 and MCL3) Studies with Long-Term Follow-up

【24h】

Targeted Sequencing of Diagnostic Samples Correlated to Clinical Outcome: Data from the Nordic Mantle Cell Lymphoma (MCL2 and MCL3) Studies with Long-Term Follow-up

机译：与临床结果相关的诊断样品的靶向测序：来自北欧套细胞淋巴瘤（MCL2和MCL3）研究的长期随访数据

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2016年第22期|共5页
作者
Eskelund Christian Winther; Hansen Jakob W.; Westman Maj Karoline; Freiburghaus Catja; Ek Sara; Pedersen Lone B.; Andersen Mette K.; Raty Riikka; Kolstad Arne; Jerkeman Mats; Brown Peter de Nully; Geisler Christian H.; Groenbaek Kirsten;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Targeted Sequencing of Diagnostic Samples Correlated to Clinical Outcome: Data from the Nordic Mantle Cell Lymphoma (MCL2 and MCL3) Studies with Long-Term Follow-up [J] . Eskelund Christian Winther, Hansen Jakob W., Westman Maj Karoline, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：与临床结果相关的诊断样品的靶向测序：来自北欧套细胞淋巴瘤（MCL2和MCL3）研究的长期随访数据
2. Molecular Monitoring and Tailored Strategy with Pre-Emptive Rituximab Treatment for Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-up of 8.5 Years [J] . Kolstad Arne, Pedersen Lone B., Eskelund Christian Winther, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：利妥昔单抗预防性治疗的分子监测和量身定制策略;北欧套细胞淋巴瘤研究（MCL2和MCL3）的结果，中位随访时间为8.5年
3. Error in a study of the outcome of mantle cell lymphoma: Nordic MCL2 Trial Update: 6-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: Still very long survival but late relapses do occur [J] . GeislerC.H., KolstadA., LaurellA., British Journal of Haematology . 2012,第6期

机译：外套细胞淋巴瘤预后研究的错误：Nordic MCL2试验更新：对未经治疗的外套细胞淋巴瘤进行强化免疫化学疗法后的6年随访，然后进行BEAM或BEAC +自体干细胞支持：存活时间仍然很长，但复发较晚确实发生
4. SHORT-TERM TUMOR RESPONSE TO TYROSINE KINASE INHIBITORS VERSUS LONG-TERM SURVIVAL IN MAST CELL TUMORS: FOLLOW-UP DATA FROM A PIVOTAL FIELD STUDY WITH MASITINIB [C] . Olivier Hermine Annual Conference of the Veterinary Cancer Society . 2009

机译：短期肿瘤对酪氨酸激酶抑制剂的反应与肥大细胞肿瘤的长期存活：来自Masitinib的关键田间研究的后续数据
5. Individual and familial correlates and outcomes of attention deficit hyperactivity disorder: A longitudinal follow-up study of a high risk sample (High-risk children). [D] . Gau, Shur-Fen Susan. 2001

机译：注意缺陷多动障碍的个体和家族相关性和结果：高风险样本（高风险儿童）的纵向随访研究。
6. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma [O] . Arne Kolstad, Anna Laurell, Mats Jerkeman, -1

机译：Nordic MCL3研究：非CR患者在套细胞淋巴瘤移植前将90Y-ibritumomab-tiuxetan加入BEAM / C
7. Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3 [O] . Christian Winther Eskelund, Kostas Dimopoulos, Arne Kolstad, 2020

机译：在北欧地幔细胞淋巴瘤试验后复发的患者的详细长期随访：MCL2和MCL3

Targeted Sequencing of Diagnostic Samples Correlated to Clinical Outcome: Data from the Nordic Mantle Cell Lymphoma (MCL2 and MCL3) Studies with Long-Term Follow-up

著录项

引文网络

相似文献

相关主题

期刊订阅